Decano, Julius L.
Dr. Julius L. Decano received his Doctorate in Medicine degree at the St. Luke’s College of Medicine and the St. Luke’s Medical Center in the Philippines and finished his pre-med bachelor’s degree in Molecular Biology and Biotechnology at the University of the Philippines, Diliman. Dr. Decano has held a post-doctoral position at the Whitaker Cardiovascular Institute of the Boston University Medical Campus (BUMC) and a managerial position at the BUMC Ultrasound Imaging Core Facility. At BUMC, Dr. Decano worked on various research projects that include: characterization of a timed spontaneous non-surgical stroke model, using juvenile protective factors like cell therapy for delaying stroke and prolonging survival among stroke-prones, and collaborated with proteomics experts to discover biochemical pathway targets in brain microvessels and blood-brain-barrier of the stroke model. These metabolic and structural targets can potentially be exploited (1) to uncover detailed mechanistic paradigms of microhemorrhages and low flow ischemia in stroke, and (2) to develop novel drugs for therapy. Dr. Decano has also done innovative work with high resolution sonographic molecular imaging of carotid vasa vasorum neovascularization in hypertensive hyperlipidemic models, as well as assessing arterial stiffness through pulsed wave imaging. While working on projects under the BU Clinical Translational Science Institute (CTSI), he did leading edge work on developing a system for delivering DNA/siRNA payload as well as inhibitory antibody therapy in a site specific manner to in vivo tissues in the live animals non-invasively. He managed to fuse ultrasound technology, molecular imaging and use of customized nanoparticles for targeted immunotherapy on spontaneous breast cancer rodent models as well as foreign gene introduction into specific tissue regions.
Dr. Decano joined CICS and Dr. Masanori Aikawa’s group in March of 2014 to continue his work on searching and testing for new translational targets for stroke and MI and to further investigate the role of macrophages in these diseases and their co-morbidities.